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The regulation of mitochondrial mass and DNA content involves a complex interaction
between mitochondrial DNA replication machinery, functional components of the electron
transport chain, selective clearance of mitochondria, and nuclear gene expression. In order
to gain insight into cellular responses to mitochondrial stress, we treated human diploid
fibroblasts with ethidium bromide at concentrations that induced loss of mitochondrial DNA
over a period of 7 days. The decrease in mitochondrial DNA was accompanied by a reduc-
tion in steady state levels of the mitochondrial DNA binding protein, TFAM, a reduction in
several electron transport chain protein levels, increased mitochondrial and total cellular
ROS, and activation of p38 MAPK. However, there was an increase in mitochondrial mass
and voltage dependent anion channel levels. In addition, mechanistic target of rapamycin
(mTOR) activity, as judged by p70S6K targets, was decreased while steady state levels of
p62/SQSTM1 and Parkin were increased. Treatment of cells with rapamycin created a sit-
uation in which cells were better able to adapt to the mitochondrial dysfunction, resulting
in decreased ROS and increased cell viability but did not prevent the reduction in mito-
chondrial DNA. These effects may be due to a more efficient flux through the electron
transport chain, increased autophagy, or enhanced AKT signaling, coupled with a reduced
growth rate. Together, the results suggest that mTOR activity is affected by mitochondrial
stress, which may be part of the retrograde signal system required for normal mitochondrial
homeostasis.
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INTRODUCTION
Mitochondrial dysfunction is associated with a variety of clin-
ical disorders including Parkinson’s disease, Friedreich ataxia,
neurodegeneration, aging, and multiple clinical myopathies, (1–
3). Integrity of the mitochondrial genome is critical to normal
function as demonstrated by pathological settings in which mito-
chondrial DNA is lost leading to a variety of clinical manifes-
tations, which include myopathic, encephalomyopathic, hepato-
cerebral, and neurogastrointestinal symptomatology (4). A direct
link between age-associated loss of function and mitochondrial
DNA integrity is supported by the fact that transgenic mice har-
boring a proof-reading deficient DNA polymerase gamma exhibit
cardiomyopathy and premature aging (5).
The circular mitochondrial genome is approximately 16,569
base pairs in humans (6), and ranges from 1000 to 8000 copies per
cell (7). The entire mitochondrial genome is dedicated to energy
production, coding for 13 electron transport chain (ETC) pro-
tein subunits 2 rRNA and 22 tRNA genes (8–10). Replication of
mtDNA is on-going throughout the cell cycle and is indepen-
dent of mitosis (11–14). Prolonged exposure to concentrations of
ethidium bromide that do not impair cell proliferation leads to
the specific loss of mitochondrial DNA. This effect is caused by
disruption of the tertiary structure of the closed circular mito-
chondrial genome following intercalation of ethidium bromide
(15) leading to inhibition of both transcription and replication
in the mitochondria without while sparing both nuclear DNA
synthesis and transcription of nuclear encoded mRNAs (16–19).
Nanogram to microgram concentrations of ethidium bromide per
milliliter of culture medium induces loss of mitochondrial DNA
and complete loss of mitochondrial DNA occurs after 5–6 weeks
of exposure (19–21), and this approach has facilitated the study of
mitochondrial mutations through introduction of specific mutant
mitochondrial genomes (19, 22). In addition, the response to mito-
chondrial DNA depletion can be examined using this approach.
Studies in cells that have lost mitochondrial DNA over a period of
weeks in culture report increased mRNA levels of genes involved in
hypoxic response, mitochondrial ribosomal proteins, solute trans-
port, and glycolytic pathways (23),while mitochondrial transcripts
are increased in cells allowed to recover from mtDNA depletion
(21, 24).
In this study, we have examined the response of human diploid
fibroblasts (HDF) to a series of concentrations of ethidium bro-
mide in order to gain a better understanding of the cellular
responses to mitochondrial stress.
MATERIALS AND METHODS
CELL CULTURE
Normal human fibroblast cells (WI-38) were cultured in Min-
imum Essential Medium Eagle (MEM) supplemented with 1%
l-glutamine, MEM amino acids and vitamins, and 10% fetal
bovine serum according to standard culture protocol (25). Cells
were maintained by trypsinization and reseeding at a cell density
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of 1× 104/cm2 every 7–10 days. All culture reagents were from
Cellgro (Manassas, VA, USA).
Cultures were exposed to ethidium bromide in full growth
medium supplemented with 50µg/ml uridine and 1 mM sodium
pyruvate containing the indicated concentrations of ethidium bro-
mide indicated in each experiment (26). For the ethidium bromide
treatment, cells were seeded at a standard density (1× 104/cm2)
according to a protocol established for the cultivation of human
mesenchymal cell cultures (27). Ethidium bromide containing
medium 24 h post seeded to ensure that the drug did not alter
cell attachment. Cultures were exposed to ethidium bromide con-
taining medium for 7 days with one change of medium. Cell
viability was assessed after ethidium bromide treatment using
trypan blue exclusion. Cells were trypsinized, re-suspended in
growth media, and diluted 1:1 using 0.4% trypan blue solution.
This mixture was incubated at room temperature for 1–2 min then
loaded onto a hemocytometer for visual assessment of dye uptake.
For cell imaging, cells were infected with a mitochondrial GFP-
containing virus from the University of Pittsburgh vector core.
Cells were exposed to virus in the presence of 10µg/ml poly-
brene and utilized as a mixed population without selection. After
treatment with ethidium bromide and/or rapamycin, cells were
imaged on an advanced microscopy group EVOS inverted fluo-
rescent microscope at a constant intensity of 20% using a 60×
objective.
ANALYSIS OF MITOCHONDRIAL DNA COPY NUMBER
Mitochondrial DNA was extracted using phenol–chloroform
extraction based upon published analysis of methods for the
optimal extraction of mitochondrial DNA (28). Total DNA was
extracted using phenol/chloroform extraction using the phase-
lock gel system (5Prime Inc., Gaithersburg, MD, USA) followed
by ethanol precipitation and a second phenol/chloroform extrac-
tion. Total DNA was quantified using a nanodrop spectropho-
tometer. Primers used to amplify mitochondrial and nuclear
DNA targeted the mitochondrial leucine tRNA transcript and the
nuclear beta-2 microglobulin gene locus. Primer sets were as fol-
lows: for leucine tRNA, 5′-CACCCAAGAACAGGGTTTGT-3′ and
5′-TGGCCATGGGTATGTTGTTA-3′: for beta-2 microglobulin,
5′-TCTCTGCTCCCCACCTCTAAGT-3′ and 5′-TGCTGTCTCGA-
TGTTTGATGTATCT-3′. Quantitative real-time PCR was per-
formed using the Verso Sybr 1 step qPCR kit (Thermo Scientific,
Waltham, MA, USA) in a Stratagene Mx3000P thermocycler.
PROTEIN ISOLATION AND IMMUNOBLOT ANALYSIS
Total protein extracts were prepared through extraction with
RIPA buffer and proteins quantified using a bicinchoninic acid
assay (Pierce Biotechnology, Rockford, IL, USA). For Western blot
analyses, 30µg of protein extracts were run on SDS-PAGE and
transferred onto Immobilon P PVDF (Millipore, Billerica, MA,
USA) or nitrocellulose (Bio-Rad, Hercules, CA, USA) membranes.
Blots were incubated with antibodies specific for p53 (Ab-6;
EMD Millipore, San Diego, CA, USA), phospho(S473)-AKT, AKT
phospho(S235/236)-ribosomal protein S6, ribosomal protein S6
(Cell Signaling, Danvers, MA, USA), p62 (Enzo Biologicals, Ply-
mouth Meeting, PA, USA), MitoProfile Total OXPHOS Cocktail
(complex I-NDUFB8 subunit, CII-SDHB subunit, CIII-UQCRC2
subunit, and CIV-mitochondrial COX1 subunit) (Abcam, Cam-
bridge, MA, USA), beta-actin (Sigma, St Louis, MO), Parkin (H-
300, Santa Cruz Biotechnologies, Santa Cruz, CA, USA), TFAM
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA), and voltage
dependent anion channel (VDAC) (4866; Cell Signaling, Beverly,
MA, USA) according to manufacturer’s instructions.
MITOCHONDRIAL POTENTIAL, MITOCHONDRIAL FUNCTION, ROS
PRODUCTION, AND MITOCHONDRIAL MASS EVALUATION
For mitochondrial potential studies, cells were incubated with
5µg/ml JC-1 (Molecular Probes, Carlsbad, CA, USA) at 37°C
in 5% CO2 for 30 min, harvested in 2.5% trypsin–EDTA, re-
suspended in 200µl of complete growth medium, and analyzed
immediately with a Guava Easy-Cyte Mini using the Guava Express
Plus program (Millipore, Billerica, MA, USA). Live-cell imaging
was performed using an EVOS FL microscope (AMG, Bothell, WA,
USA) immediately following the 30-min incubation period. For
mitochondrial mass evaluation, cells were incubated for 30 min in
100 nM MitoTracker Green FM (Molecular Probes, Carlsbad, CA,
USA) at 37°C, harvested in 2.5% trypsin–EDTA, and re-suspended
in 200µl complete growth medium. Cells were analyzed imme-
diately with a Guava Easy-Cyte Mini using the Guava Express
Plus program. Mitochondrial ROS was measured by incubating
cells with MitoSox superoxide anion indicator (Molecular Probes,
Carlsbad, CA, USA) at 5µM for 10 min in growth medium at
37°C in 5% CO2 for 10 min. Cells were trypsinized as above
and analyzed using a Guava Easy-Cyte Mini using the Guava
Express Plus program. Total cellular ROS was assessed using
2,7-dichlorodihydrofluorescein diacetate (DCFH-DA). Cells were
seeded in triplicate wells and following a 24–48-h attachment
period, cells were trypsinized, washed with phosphate buffered
saline, and re-suspended in PBS containing 10µM DCFH-DA.
Following a 30-min incubation, cells were collected by centrifuga-
tion, re-suspended in PBS, and analyzed by flow cytometry using
a Guava Easy-Cyte Mini flow cytometer.
STATISTICAL ANALYSIS
Unless otherwise stated in figure legend, all results are expressed
as average plus or minus standard deviation of three independent
samples. Significance was assessed with the unpaired, two tailed
Student’s t -test.
RESULTS
Human diploid fibroblasts were exposed to ethidium bromide at
concentrations ranging from 10 to 100 ng/ml for 7 days. Under
these conditions, we found a dose-dependent decline in the mito-
chondrial DNA content (Figure 1). We have previously found that
long-term exposure to nanomolar concentrations of rapamycin
increases replicative lifespan of HDF, reduces the percent of cells
with depolarized mitochondria, and increases the expression of
genes associated with mitochondrial biogenesis (25, 29). We uti-
lized this paradigm to examine the response of rapamycin treated
cells to a direct mitochondrial insult such as ethidium bro-
mide exposure. When HDF were grown in the presence of 1 nM
rapamycin and exposed to ethidium bromide, we found a simi-
lar reduction in mitochondrial DNA content, although the initial
copy number was lower than control cultures (Figure 1).
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FIGURE 1 | Ethidium bromide exposure leads to a loss of
mitochondrial DNA. Human fibroblast cell cultures grown in the presence
or absence of 1 nM rapamycin were exposed to increasing doses of
ethidium bromide for a period of 7 days. At this time, the relative level of
mitochondrial DNA was assessed using real-time PCR analysis as
described in Section “Materials and Methods.” Gray bars indicate control
cultures and black bars indicate rapamycin treated cultures. The
concentration of ethidium bromide is indicated beneath each bar.
Differences between cultures exposed to ethidium bromide and
unexposed cultures, which are significant at P <0.05 are indicated by an
asterisk and differences between control and rapamycin treated cultures
under identical conditions are indicated by a pound sign. The graph contains
a representative experiment of a minimum of three independent replicates
with similar results and significance.
We examined several aspects of mitochondria following ethid-
ium bromide exposure. Both mitochondrial-specific and total
cellular ROS were increased in cells that were exposed to ethid-
ium bromide (Figure 2). Pretreatment of HDF with rapamycin
decreased both the baseline levels of cellular ROS and signifi-
cantly reduced the effect of ethidium bromide on the produc-
tion of ROS (Figure 2). Similarly, the baseline levels of mito-
chondrial ROS levels and the mitochondrial ROS induced by
ethidium bromide were significantly reduced by rapamycin pre-
treatment (Figure 2). The percent of cells with depolarized
mitochondria was increased following ethidium bromide treat-
ment and this percentage was reduced by pretreatment with
rapamycin (Figure 3). Despite the reduction in mitochondr-
ial DNA, mitochondrial mass was increased following ethid-
ium bromide treatment in a dose-dependent manner, while
HDF grown in the presence of rapamycin had a greater mito-
chondrial mass that was not altered by ethidium bromide
(Figure 4).
In order to gain further insight into the changes in mitochon-
drial mass following ethidium bromide exposure, we examined
the steady state levels of several resident mitochondrial proteins.
Consistent with the reduction in mitochondrial DNA content,
the steady state levels of the mitochondrial transcription factor
(TFAM) decreased in both control and rapamycin treated HDFs
upon exposure to ethidium bromide (Figure 5). In contrast, the
steady state levels of the VDAC increased in control HDF cul-
tures upon exposure to ethidium bromide (Figure 5). The baseline
levels of VDAC were lower than controls in rapamycin treated cul-
tures but these levels did not change upon exposure to ethidium
bromide (Figure 5).
We next examined the steady state levels of a subset of the
ETC proteins. The NADH dehydrogenase (ubiquinone) 1 beta
subcomplex subunit 8 (NDUFB8) of complex 1, ubiquinol–
cytochrome c reductase core protein II (UQCRC2) of complex III,
and cytochrome c oxidase subunit I (mtCO1) of complex IV were
all reduced following exposure to ethidium bromide (Figure 5).
In contrast, the steady state levels of succinate dehydrogenase
(ubiquinone) iron–sulfur subunit (SDHB) of complex II and the
ATP synthase alpha subunit 1 (ATP5A), were not affected by expo-
sure to ethidium bromide (Figure 5). In HDF cells treated with
rapamycin, the steady state levels of all ETC proteins was lower
than control cultures under normal growth conditions except for
the levels of ATP5A, which were similar to controls and were not
affected by ethidium bromide (Figure 5).
We examined proteins associated with autophagy in HDF cul-
tures exposed to ethidium bromide. The steady state level of
p62 sequestasome 1 (p62/SQSMTM1) increased in HDF cul-
tures exposed to ethidium bromide but was uniformly lower in
HDF cultures that had been treated with rapamycin (Figure 6).
Both the unconjugated form of microtubule-associated protein
light chain 3(LC3B-I) and the conjugated form of LC3 (LC3B-
II) decreased following exposure to ethidium bromide (Figure 6),
while rapamycin treated cultures showed reduced levels of both
LC3B-I and LC3B-II that were not affected by exposure to ethid-
ium bromide. We also examined the steady state levels of Parkin,
a protein involved in mitochondrial turnover (30–32). The steady
state levels of Parkin increased following exposure to ethidium
bromide, while Parkin levels were uniformly elevated in rapamycin
treated cultures relative to control cultures (Figure 6). The lev-
els of both NRF1 and NFE2L2 (NRF2) were increased following
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FIGURE 2 | Mitochondrial and total cellular ROS production. Human
fibroblast cell cultures grown in the presence or absence of 1 nM rapamycin
were exposed to increasing doses of ethidium bromide for a period of 7 days.
At this time, mitochondrial ROS and cellular ROS were measured as
described in Section “Materials and Methods.” (A) Mitochondrial ROS
production is presented. Gray bars indicate control cultures and black bars
indicate rapamycin treated cultures. (B) Relative levels of total cellular ROS
are presented. The concentration of ethidium bromide is indicated beneath
each bar. Differences between cultures exposed to ethidium bromide and
unexposed cultures, which are significant at P <0.05 are indicated by an
asterisk and differences between control and rapamycin treated cultures
under identical conditions are indicated by a pound sign. The graph contains a
representative experiment of a minimum of three independent replicates with
similar results and significance.
exposure to ethidium bromide. Rapamycin treatment increased
the levels of both proteins in normal growth conditions, consis-
tent with our previous observations (29), while ethidium bromide
exposure did not increase the levels of NRF1 and NFE2L2 further
(Figure 6).
We examined downstream targets of the mechanistic target of
rapamycin (mTOR) pathway, and found the serine phosphory-
lation of S6 ribosomal protein, the insulin receptor substrate 1
(IRS-1), and Akt were all reduced following exposure to ethidium
bromide consistent with reduced mTOR activity (Figure 7). In
addition, the phosphorylation of the p38 MAPK stress kinase was
increased by exposure to ethidium bromide as was the phospho-
rylation of the p38MAPK downstream target, heat shock protein
27 (hsp27) (Figure 8A). Levels of p53 protein were increased in
cells exposed to ethidium bromide (Figure 8A) while neither the
phosphorylation of 38, hsp27, nor the increase in p53 occurred if
cells were treated with rapamycin (Figure 8). Treatment of cells
with rapamycin also significantly increased viability at 7 days of
exposure to ethidium bromide at the highest concentrations used
in our studies (Figure 8B).
DISCUSSION
Ethidium bromide induces a cell stress that is caused by progressive
loss of mitochondrial function, membrane depolarization, and
ROS production. These results are counteracted by the cell in an
attempt to maintain vital aspects of mitochondrial activity while
targeting problematic mitochondria for clearance. Autophagy is an
important pathway for the clearance of dysfunctional mitochon-
dria and a recent report indicates that mitochondrial clearance fol-
lowing exposure to ethidium bromide occurs through autophagy
(33) suggesting that autophagy is likely to be an important aspect
of cellular responses to depletion of mitochondrial DNA.
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FIGURE 3 | Loss of mitochondrial membrane potential following
exposure to ethidium bromide. Human fibroblast cell cultures grown in
the presence or absence of 1 nM rapamycin were exposed to increasing
doses of ethidium bromide for a period of 7 days. At this time,
mitochondrial membrane potential was assessed as described in Section
“Materials and Methods.” Gray bars indicate control cultures and black
bars indicate rapamycin treated cultures. The concentration of ethidium
bromide is indicated beneath each bar. Differences between cultures
exposed to ethidium bromide and unexposed cultures, which are
significant at P <0.05 are indicated by an asterisk and differences
between control and rapamycin treated cultures under identical conditions
are indicated by a pound sign. The graph contains a representative
experiment of a minimum of two independent replicates with similar
results and significance.
FIGURE 4 | Mitochondrial mass following exposure to ethidium bromide.
Human fibroblast cell cultures grown in the presence or absence of 1 nM
rapamycin were exposed to increasing doses of ethidium bromide for a period
of 7 days. At this time, mitochondrial mass was assessed using MitoTracker
green as described in Section “Materials and Methods.” Gray bars indicate
control cultures and black bars indicate rapamycin treated cultures. The
concentration of ethidium bromide is indicated beneath each bar. Differences
between cultures exposed to ethidium bromide and unexposed cultures,
which are significant at P <0.05 are indicated by an asterisk and differences
between control and rapamycin treated cultures under identical conditions are
indicated by a pound sign.The graph contains a representative experiment of a
minimum of two independent replicates with similar results and significance.
Inhibition of the mTOR complex by treatment of cells
with rapamycin is a strong inducer of autophagy and appears
to improve mitochondrial homeostasis. Rapamycin treatment
increases lifespan in mice, and cultured human cells, and prevents
the progressive loss of mitochondrial membrane potential that
normally occurs with increasing passage number (29, 34, 35). In
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FIGURE 5 | Steady state levels of mitochondrial proteins following
ethidium bromide exposure. Human fibroblast cell cultures grown in the
presence or absence of 1 nM rapamycin were exposed to increasing doses
of ethidium bromide for a period of 7 days. At this time, total cellular protein
extracts were prepared and analyzed by immunoblot as described in
Section “Materials and Methods” for a subset of mitochondrial resident
proteins. The levels of beta-actin are presented as a control for equal
protein loading. The immunoblot presented is a representative blot of a
minimum of two measurements with similar results.
FIGURE 6 | Steady state levels of proteins involved in mitochondrial
clearance and biogenesis following ethidium bromide exposure.
Human fibroblast cell cultures grown in the presence or absence of 1 nM
rapamycin were exposed to increasing doses of ethidium bromide for a
period of 7 days. At this time, total cellular protein extracts were prepared
and analyzed by immunoblot as described in Section “Materials and
Methods” for a subset of mitochondrial resident proteins. The levels of
beta-actin or beta tubulin are presented as a control for equal protein
loading. The immunoblot presented is a representative blot of a minimum
of two measurements with similar results.
addition, rapamycin alleviates mitochondrial disease in a mouse
model of Leigh syndrome (36). Here, we find that rapamycin treat-
ment of human fibroblasts also preserves mitochondrial mem-
brane potential when cells are exposed to ethidium bromide and
reduces both mitochondrial ROS production and total cellular
FIGURE 7 | Phosphorylation state of ribosomal S6, IRS-1, and Akt
proteins following ethidium bromide exposure. Human fibroblast cell
cultures grown in the presence or absence of 1 nM rapamycin were
exposed to increasing doses of ethidium bromide for a period of 7 days. At
this time, total cellular protein extracts were prepared and analyzed by
immunoblot as described in Section “Materials and Methods” for a subset
of mitochondrial resident proteins. The levels of beta-actin are presented as
a control for equal protein loading. The immunoblot presented is a
representative blot of a minimum of two measurements with similar
results.
ROS. Additionally, cells treated with rapamycin showed a signif-
icant reduction in stress signaling activation (as judged by p38
MAPK activity) and an increase in viability following 7 days expo-
sure to ethidium bromide. This suggests that some aspects of
changes induced by mTOR inhibition enhanced the ability of cells
to adjust to the stress of ethidium bromide. One possibility is
that the relative rate of autophagy was increased in cells treated
with rapamycin. We have shown that treatment with nanomolar
concentrations of rapamycin enhanced autophagy (29). In con-
trast, the increase in steady state levels of p62/SQSTM1 in cells
exposed to ethidium bromide suggests an inhibition of autophagy
(see Figure 6), since p62SQS/TM1 levels generally reflects the rate
of autophagy, due to the fact that this protein facilitates delivery of
proteins to the autophagosome and is itself degraded during this
process (37). In contrast, cells treated with rapamycin exhibited
a relatively low level of p62/SQSTM1 consistent with enhanced
autophagy together with an elevated level of Parkin, and it is pos-
sible that this shift in autophagy was protective to cells exposed to
ethidium bromide.
A second possibility for the protective effects of rapamycin may
be a more efficient flux through the ETC. Previous work from
our laboratory indicates that rapamycin treatment reduced elec-
tron transport chain activity but preserved functionality in the
face of oxidative challenge (29). Our current analysis of electron
transport chain proteins revealed that steady state levels of sev-
eral ETC components were reduced but both SDHB and ATP5A
were maintained when cells were exposed to ethidium bromide
(see Figure 5). In contrast, in cells that had been treated with
rapamycin, the steady state levels of the majority of ETC com-
ponents were reduced relative to control cells. One difference in
the rapamycin treated cells at baseline (no ethidium bromide) was
that the relative level or ATP5A to other ETC components was
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FIGURE 8 | Stress kinase signaling, p53 levels, and cell viability
following ethidium bromide exposure. Human fibroblast cell cultures
grown in the presence or absence of 1 nM rapamycin were exposed to
increasing doses of ethidium bromide for a period of 7 days. (A)Total
cellular protein extracts were prepared and analyzed by immunoblot as
described in Section “Materials and Methods” for a subset of mitochondrial
resident proteins. The levels of beta-actin are presented as a control for
equal protein loading. The immunoblot presented is a representative blot of
a minimum of two measurements with similar results. (B) Cells were
examined for viability using a trypan blue exclusion assay. Gray bars
indicate control cultures and black bars indicate rapamycin treated cultures.
The concentration of ethidium bromide is indicated beneath each bar.
Differences between cultures exposed to ethidium bromide and unexposed
cultures, which are significant at P <0.05 are indicated by an asterisk and
differences between control and rapamycin treated cultures under identical
conditions are indicated by a pound sign.
increased. It is possible that the altered stoichiometry of the ETC
components differed between control and rapamycin treated cells
contributed to the reduced mitochondrial and cellular ROS levels
relative to control cultures (compare untreated cells in gray bars
to rapamycin treated in black bars in Figure 2).
A third, not mutually exclusive, possibility underlying the
protective effects of rapamycin involves the differences in phos-
phorylation status of key second messenger proteins. Exposure
to ethidium bromide caused a decrease in the phosphorylated
form of the ribosomal S6 protein, suggesting an inhibition of
mTORC1 activity. In addition, exposure to ethidium bromide
caused a reduction in serine phosphorylation of both IRS-1 and
Akt1 while the phosphorylation status of these proteins was main-
tained in cultures treated with rapamycin (Figure 7). Inhibition
of mTOR has been shown to inhibit proteasomal degradation of
IRS-1 (38–40) enhancing signaling through the PI-3 kinase/Akt
pathway. Because Akt is known to antagonize apoptotic processes
and has a complex relationship with mTOR signaling as it is both
regulated by TORC2 and acts to regulate TORC1 activity (41), dif-
ferences in Akt activity could contribute to the enhanced survival
of cells treated with rapamycin. The increase in Akt phosphoryla-
tion is interesting when considered in the light of the reduced
growth rate of cells maintained in the presence of rapamycin
(29). In previous work, we have reported that proliferation of
the human fibroblasts was significantly reduced under our culture
conditions (full growth medium plus 1 nM rapamycin) but the
culture was able to attain a higher number of population dou-
blings prior to entering the senescent state (25, 29). In addition,
rapamycin treated cultures displayed an increase in mitochondr-
ial biogenesis and a reduction in the mitochondrial membrane
depolarization that we and others have observed at higher pop-
ulation doublings in human fibroblasts (29, 42). In the present
study, cultures were exposed to ethidium bromide shortly after
seeding and were allowed to proliferate for 7 days. Interestingly,
when cells were exposed to ethidium bromide with and with-
out rapamycin treatment, we observed that the cell number was
higher in rapamycin treated cultures after 1-week NRTI treatment
period. We reported a similar paradoxical increase in clonal growth
of cells treated with rapamycin when cells were exposed to IGF-1
while maintained in a non-dividing state (25) prior to reseeding
in full growth medium. As with the present study, several parame-
ters of mitochondrial function were improved in these conditions
suggesting that rapamycin enhanced mitochondrial homeostasis.
Thus, it appears that the protective effects of rapamycin are com-
plex, involving shifts in phosphorylation cascades, steady state
levels of ETC proteins, reduced proliferation, and an increased
rate of autophagy leading to greater viability.
In summary, our results indicate that ethidium bromide expo-
sure induces a loss of mitochondrial DNA, a reduction in several
ETC protein levels, and increased ROS while increasing mitochon-
drial mass. We interpret this increase in mitochondrial mass as
reflective of a mechanism that endeavors to maintain mitochon-
drial activity but which cannot compensate for the progressive loss
of mitochondrial-specific gene expression, resulting in a progres-
sive loss of mitochondrial membrane potential concomitant with
an increased ROS production. Treatment of cells with rapamycin
created a situation in which cells were better able to adapt to
the mitochondrial dysfunction, resulting in decreased ROS and
increased cell viability.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fendo.2014.00122/
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